ANAHEIM, Calif., July 24 /PRNewswire/ -- Elekta CMS Software has received FDA 510(k) clearance for the VMAT enhancement to Monaco((R)), an advanced IMRT treatment planning solution that combines new levels of scientific insight with precise dose control.
Monaco with VMAT can optimize single or multiple non-coplanar arcs simultaneously, providing the flexibility and control needed for complex treatment plans. Reducing planning time and increasing clinical throughput, arc plans can be delivered with a single button push at the linear accelerator console, gantry directions automatically sorted and control points seamlessly integrated into a single deliverable arc sequence.
Monaco has been available for use clinically for the past two years for step-and-shoot IMRT planning. The product was developed in cooperation with Eberhard Karls Universitat Tuebingen in Germany.
A new paradigm in VMAT planning, Monaco incorporates biologically based objectives, constrained optimization, sensitivity analysis and unique smart sequencing. In addition, Monaco is the only planning platform that offers the accurate XVMC Monte Carlo dose engine for a continuous arc calculation as a single beam. The result gives clinicians the power to provide higher standard of patient care.
"We are extremely proud and very pleased to receive clearance to add this VMAT technique to Monaco in the U.S. market," said Rob Cessac, Product Manager for Elekta CMS Software. "Our continued support and development of leading approaches to cancer treatment promises to create a positive future for clinicians and patients."
For the latest Monaco with VMAT news, visit www.elekta.com/cms.
Elekta is a human care company pioneering significant innovations and clinical solution
Copyright©2009 PR Newswire.
All rights reserved